BridgeBio (BBIO) Q2 2025 Earnings Transcript [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Chief Financial Officer and President — Thomas Trimarchi Chief Commercial Officer — Matthew Outten Senior Vice President, Strategic Finance — Chinmay Shukla Leader, ADH1 Phase III Program — Ananth Sridhar Leader, LGMD2I Phase III Program — Christine Siu Leader, Achondroplasia Phase III Program — Justin To Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Chinmay Shukla: Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. I'm Chinmay Shukla, Senior Vice President of Strategic Finance at BridgeBio. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom Trimarchi, our President and Chief Financial Officer. During today's call, we will cover our strong and accelerating launch of Attruby. We will provide updates on our late-stage pipeline, including the 3 key Phase III trials in ADH1, LGMD2I and achondroplasia. Following our prepared remarks, we
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $95.00 to $102.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio (BBIO) Q2 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Mizuho. They now have a $106.00 price target on the stock.MarketBeat
- BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White [Yahoo! Finance]Yahoo! Finance
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form ARS
- 4/24/26 - Form DEF
- BBIO's page on the SEC website